Dena M Carbonari1,2, M Elle Saine1,2, Craig W Newcomb1, Betina Blak3, Jason A Roy1,2, Kevin Haynes1,2,4, Jennifer Wood5, Arlene M Gallagher6, Harshvinder Bhullar7, Serena Cardillo8, Sean Hennessy1,2, Brian L Strom1,2,9, Vincent Lo Re1,2,8. 1. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 2. Center for Pharmacoepidemiology Research and Training, Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 3. AstraZeneca UK Limited, London, UK. 4. HealthCore, Inc., Wilmington, DE, USA. 5. Department of Global Pharmacovigilance and Epidemiology, Bristol-Myers Squibb, Hopewell, NJ, USA. 6. Clinical Practice Research Datalink, London, UK. 7. IMS Health, London, UK. 8. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 9. Rutgers Biomedical and Health Sciences, Rutgers, the State University of New Jersey, Newark, NJ, USA.
Abstract
PURPOSE: Pharmacoepidemiology researchers often utilize data from two UK electronic medical record databases, the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN), and may choose to combine the two in an effort to increase sample size. To minimize duplication of data, previous studies examined the practice-level overlap between these databases. However, the proportion of overlapping patients remains unknown. We developed a method using demographic and pharmacy variables to identify patients included in both CPRD and THIN, and applied this method to measure the proportion of overlapping patients who initiated the oral anti-diabetic drug saxagliptin. METHODS: We conducted a cross-sectional study among patients initiating saxagliptin in CPRD and THIN between October 2009 and September 2012. Within both databases, we identified patients: (i) ≥18 years, (ii) newly prescribed saxagliptin, and (iii) with ≥180 days enrollment prior to saxagliptin initiation. Demographic data (birth year, sex, patient registration date, family number, and marital status) and prescriptions (including dates) for the first two oral anti-diabetic drugs prescribed within the study period were used to identify matching patients. RESULTS: Among 4202 CPRD and 3641 THIN patients initiating saxagliptin, 2574 overlapping patients (61% of CPRD saxagliptin initiators; 71% of THIN saxagliptin initiators) were identified. Among these patients, 2474 patients (96%) perfectly matched on all demographic and prescription data. CONCLUSIONS: Within each database, over 60% of patients initiating saxagliptin were included within both CPRD and THIN. Combined demographic and prescription data can be used to identify patients included in both CPRD and THIN.
PURPOSE: Pharmacoepidemiology researchers often utilize data from two UK electronic medical record databases, the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN), and may choose to combine the two in an effort to increase sample size. To minimize duplication of data, previous studies examined the practice-level overlap between these databases. However, the proportion of overlapping patients remains unknown. We developed a method using demographic and pharmacy variables to identify patients included in both CPRD and THIN, and applied this method to measure the proportion of overlapping patients who initiated the oral anti-diabetic drug saxagliptin. METHODS: We conducted a cross-sectional study among patients initiating saxagliptin in CPRD and THIN between October 2009 and September 2012. Within both databases, we identified patients: (i) ≥18 years, (ii) newly prescribed saxagliptin, and (iii) with ≥180 days enrollment prior to saxagliptin initiation. Demographic data (birth year, sex, patient registration date, family number, and marital status) and prescriptions (including dates) for the first two oral anti-diabetic drugs prescribed within the study period were used to identify matching patients. RESULTS: Among 4202 CPRD and 3641 THIN patients initiating saxagliptin, 2574 overlapping patients (61% of CPRD saxagliptin initiators; 71% of THIN saxagliptin initiators) were identified. Among these patients, 2474 patients (96%) perfectly matched on all demographic and prescription data. CONCLUSIONS: Within each database, over 60% of patients initiating saxagliptin were included within both CPRD and THIN. Combined demographic and prescription data can be used to identify patients included in both CPRD and THIN.
Authors: Kirsten J Lum; Craig W Newcomb; Jason A Roy; Dena M Carbonari; M Elle Saine; Serena Cardillo; Harshvinder Bhullar; Arlene M Gallagher; Vincent Lo Re Journal: Eur J Clin Pharmacol Date: 2016-10-27 Impact factor: 2.953
Authors: Vincent Lo Re; Dena M Carbonari; M Elle Saine; Craig W Newcomb; Jason A Roy; Qing Liu; Qufei Wu; Serena Cardillo; Kevin Haynes; Stephen E Kimmel; Peter P Reese; David J Margolis; Andrea J Apter; K Rajender Reddy; Sean Hennessy; Harshvinder Bhullar; Arlene M Gallagher; Daina B Esposito; Brian L Strom Journal: BMJ Open Diabetes Res Care Date: 2017-07-31
Authors: Evangelos Kontopantelis; Richard John Stevens; Peter J Helms; Duncan Edwards; Tim Doran; Darren M Ashcroft Journal: BMJ Open Date: 2018-02-28 Impact factor: 2.692
Authors: Anu Jain; Albert J van Hoek; Jemma L Walker; Rohini Mathur; Liam Smeeth; Sara L Thomas Journal: PLoS One Date: 2017-11-30 Impact factor: 3.240
Authors: Caroline van Durme; Bart Spaetgens; Johanna Driessen; Johannes Nielen; Manuel Sastry; Annelies Boonen; Frank de Vries Journal: Arthritis Res Ther Date: 2020-04-25 Impact factor: 5.156
Authors: Chao Zeng; Kim Bennell; Zidan Yang; Uyen-Sa D T Nguyen; Na Lu; Jie Wei; Guanghua Lei; Yuqing Zhang Journal: Ann Rheum Dis Date: 2020-09-16 Impact factor: 19.103